human dlbcl cell lines u-2932 Search Results


human dlbcl cells  (ATCC)
95
ATCC human dlbcl cells
The reciprocal repression effect of LINC00908 and miR-671-5p. ( A ) Subcellular fractionation assay was used to determine the subcellular localization of LINC00908. ( B ) Expression levels of miR-671-5p <t>in</t> <t>U2932</t> and FARAGE cells after the knockdown of LINC00908. ( C ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p mimic. ( D ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p inhibitor. ( E ) Expression of miR-671-5p in 28 <t>DLBCL</t> tissues and paired normal tissues based on qRT-PCR. ( F ) The association between LINC00908 and miR-671-5p was examined. ( G ) Expression of miR-671-5p in the GB12878 cells and DLBCL cell lines based on qRT-PCR. **p < 0.01.
Human Dlbcl Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dlbcl cells/product/ATCC
Average 95 stars, based on 1 article reviews
human dlbcl cells - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
diffuse large b cell lymphoma dlbcl derived cell lines  (DSMZ)
93
DSMZ diffuse large b cell lymphoma dlbcl derived cell lines
The reciprocal repression effect of LINC00908 and miR-671-5p. ( A ) Subcellular fractionation assay was used to determine the subcellular localization of LINC00908. ( B ) Expression levels of miR-671-5p <t>in</t> <t>U2932</t> and FARAGE cells after the knockdown of LINC00908. ( C ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p mimic. ( D ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p inhibitor. ( E ) Expression of miR-671-5p in 28 <t>DLBCL</t> tissues and paired normal tissues based on qRT-PCR. ( F ) The association between LINC00908 and miR-671-5p was examined. ( G ) Expression of miR-671-5p in the GB12878 cells and DLBCL cell lines based on qRT-PCR. **p < 0.01.
Diffuse Large B Cell Lymphoma Dlbcl Derived Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/diffuse large b cell lymphoma dlbcl derived cell lines/product/DSMZ
Average 93 stars, based on 1 article reviews
diffuse large b cell lymphoma dlbcl derived cell lines - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
human abc dlbcl cell line u2932  (DSMZ)
94
DSMZ human abc dlbcl cell line u2932
Volcano plot showing sex differences in gene expression in <t>DLBCL.</t> Genes were considered to be differentially expressed when adjusted p -value < 0.05. Upregulated genes are marked in red, downregulated genes are marked in green, and not significant genes are marked in black.
Human Abc Dlbcl Cell Line U2932, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human abc dlbcl cell line u2932/product/DSMZ
Average 94 stars, based on 1 article reviews
human abc dlbcl cell line u2932 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
human dlbcl cell lines  (ATCC)
95
ATCC human dlbcl cell lines
The gene expression profiling interactive analysis through the GEPIA software. <t>DLBCL</t> data were analyzed in TCGA and GTEx databases through the GEPIA web-based software, showing that G9a was more highly expressed in DLBCL tumor tissues than in normal tissues. Abbreviations: The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx), adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), uveal melanoma (UVM) (*, p < 0.05).
Human Dlbcl Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dlbcl cell lines/product/ATCC
Average 95 stars, based on 1 article reviews
human dlbcl cell lines - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
dlbcl cell lines  (DSMZ)
95
DSMZ dlbcl cell lines
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Dlbcl Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlbcl cell lines/product/DSMZ
Average 95 stars, based on 1 article reviews
dlbcl cell lines - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
human dlbcl cell lines u-2932  (Procell Inc)
90
Procell Inc human dlbcl cell lines u-2932
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Human Dlbcl Cell Lines U 2932, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dlbcl cell lines u-2932/product/Procell Inc
Average 90 stars, based on 1 article reviews
human dlbcl cell lines u-2932 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human abc dlbcl cell lines  (ATCC)
95
ATCC human abc dlbcl cell lines
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Human Abc Dlbcl Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human abc dlbcl cell lines/product/ATCC
Average 95 stars, based on 1 article reviews
human abc dlbcl cell lines - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
cell line u-2932  (DSMZ)
90
DSMZ cell line u-2932
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Cell Line U 2932, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell line u-2932/product/DSMZ
Average 90 stars, based on 1 article reviews
cell line u-2932 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
murine b-cell lymphoma a20 cells  (Procell Inc)
90
Procell Inc murine b-cell lymphoma a20 cells
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Murine B Cell Lymphoma A20 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine b-cell lymphoma a20 cells/product/Procell Inc
Average 90 stars, based on 1 article reviews
murine b-cell lymphoma a20 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
oci ly 19  (DSMZ)
95
DSMZ oci ly 19
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Oci Ly 19, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oci ly 19/product/DSMZ
Average 95 stars, based on 1 article reviews
oci ly 19 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


The reciprocal repression effect of LINC00908 and miR-671-5p. ( A ) Subcellular fractionation assay was used to determine the subcellular localization of LINC00908. ( B ) Expression levels of miR-671-5p in U2932 and FARAGE cells after the knockdown of LINC00908. ( C ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p mimic. ( D ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p inhibitor. ( E ) Expression of miR-671-5p in 28 DLBCL tissues and paired normal tissues based on qRT-PCR. ( F ) The association between LINC00908 and miR-671-5p was examined. ( G ) Expression of miR-671-5p in the GB12878 cells and DLBCL cell lines based on qRT-PCR. **p < 0.01.

Journal: Cancer Management and Research

Article Title: LINC00908 Promotes Diffuse Large B-Cell Lymphoma Development by Down-Regulating miR-671-5p

doi: 10.2147/CMAR.S299715

Figure Lengend Snippet: The reciprocal repression effect of LINC00908 and miR-671-5p. ( A ) Subcellular fractionation assay was used to determine the subcellular localization of LINC00908. ( B ) Expression levels of miR-671-5p in U2932 and FARAGE cells after the knockdown of LINC00908. ( C ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p mimic. ( D ) qPCR analysis of LINC00908 after cells were transfected with miR-671-5p inhibitor. ( E ) Expression of miR-671-5p in 28 DLBCL tissues and paired normal tissues based on qRT-PCR. ( F ) The association between LINC00908 and miR-671-5p was examined. ( G ) Expression of miR-671-5p in the GB12878 cells and DLBCL cell lines based on qRT-PCR. **p < 0.01.

Article Snippet: Human lymphoblastoid B cell (GM12878) and human DLBCL cells (OCI-LY7, DB, U2932, and FARAGE) were purchased from American Type Culture Collection (ATCC).

Techniques: Fractionation, Expressing, Knockdown, Transfection, Quantitative RT-PCR

Volcano plot showing sex differences in gene expression in DLBCL. Genes were considered to be differentially expressed when adjusted p -value < 0.05. Upregulated genes are marked in red, downregulated genes are marked in green, and not significant genes are marked in black.

Journal: Cancers

Article Title: Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects

doi: 10.3390/cancers15041298

Figure Lengend Snippet: Volcano plot showing sex differences in gene expression in DLBCL. Genes were considered to be differentially expressed when adjusted p -value < 0.05. Upregulated genes are marked in red, downregulated genes are marked in green, and not significant genes are marked in black.

Article Snippet: The human ABC DLBCL cell line U2932 used in this study was obtained from DSMZ (Leibniz Institute, Braunschweig, Germany) and cultured as previously described [ ].

Techniques: Gene Expression

Sex differences in gene expression and pathways among molecular subtypes of DLBCL. ( A ), Venn diagram showing the distribution of the differentially expressed genes among the DLBCL subtypes (adj. p -value < 0.05). The table shows the number of samples for each subtype and sex. ( B ), Venn diagram depicting the significant pathways showing a sex difference among the DLBCL subtypes as analyzed by GSEA (adj. p -value < 0.05).

Journal: Cancers

Article Title: Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects

doi: 10.3390/cancers15041298

Figure Lengend Snippet: Sex differences in gene expression and pathways among molecular subtypes of DLBCL. ( A ), Venn diagram showing the distribution of the differentially expressed genes among the DLBCL subtypes (adj. p -value < 0.05). The table shows the number of samples for each subtype and sex. ( B ), Venn diagram depicting the significant pathways showing a sex difference among the DLBCL subtypes as analyzed by GSEA (adj. p -value < 0.05).

Article Snippet: The human ABC DLBCL cell line U2932 used in this study was obtained from DSMZ (Leibniz Institute, Braunschweig, Germany) and cultured as previously described [ ].

Techniques: Gene Expression

Venn diagram showing the number of genes that are differentially expressed in pre- vs. postmenopausal females among the ABC and GCB subtypes and the overlap of differentially expressed genes in pre- (≤52 years of age) vs. post (≥65 years of age)-menopausal females in the ABC and GCB DLBCL subtypes (adj. p -value < 0.05). The table shows the number of DLBCL cases in the ABC and GCB subgroups and in pre- and postmenopausal females, respectively. * This is the explanation (the names) of the five genes that overlap between the GCG and ABC subtypes of female pre- vs. postmenopausal patients.

Journal: Cancers

Article Title: Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects

doi: 10.3390/cancers15041298

Figure Lengend Snippet: Venn diagram showing the number of genes that are differentially expressed in pre- vs. postmenopausal females among the ABC and GCB subtypes and the overlap of differentially expressed genes in pre- (≤52 years of age) vs. post (≥65 years of age)-menopausal females in the ABC and GCB DLBCL subtypes (adj. p -value < 0.05). The table shows the number of DLBCL cases in the ABC and GCB subgroups and in pre- and postmenopausal females, respectively. * This is the explanation (the names) of the five genes that overlap between the GCG and ABC subtypes of female pre- vs. postmenopausal patients.

Article Snippet: The human ABC DLBCL cell line U2932 used in this study was obtained from DSMZ (Leibniz Institute, Braunschweig, Germany) and cultured as previously described [ ].

Techniques:

Identification of genes that likely are regulated by estrogens in the ABC and GCB DLBCL subtypes, respectively. ( A ), Venn diagram showing the overlap of differentially expressed genes in the ABC DLBCL subtype. ( B ), Bar graph showing the log2-fold change of genes that are likely regulated by estrogen in the ABC subtype. Upregulated genes are marked in red, and downregulated genes are marked in blue. ( C ), Venn diagram showing the overlap of differentially expressed genes in the GCB DLBCL subtype. ( D ), Bar graph showing the log2-fold change of genes that are likely regulated by estrogens in the GCB subtype. Upregulated genes are marked in red, and downregulated genes are marked in blue.

Journal: Cancers

Article Title: Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects

doi: 10.3390/cancers15041298

Figure Lengend Snippet: Identification of genes that likely are regulated by estrogens in the ABC and GCB DLBCL subtypes, respectively. ( A ), Venn diagram showing the overlap of differentially expressed genes in the ABC DLBCL subtype. ( B ), Bar graph showing the log2-fold change of genes that are likely regulated by estrogen in the ABC subtype. Upregulated genes are marked in red, and downregulated genes are marked in blue. ( C ), Venn diagram showing the overlap of differentially expressed genes in the GCB DLBCL subtype. ( D ), Bar graph showing the log2-fold change of genes that are likely regulated by estrogens in the GCB subtype. Upregulated genes are marked in red, and downregulated genes are marked in blue.

Article Snippet: The human ABC DLBCL cell line U2932 used in this study was obtained from DSMZ (Leibniz Institute, Braunschweig, Germany) and cultured as previously described [ ].

Techniques:

Representative immunohistochemistry staining of DLBCL lymphoma tissue for NR4A2 ( A ) and MUC5B ( B ). Immunohistochemical staining of DLBCL for NR4A2 ( A ) and MUC5B ( B ). Representative staining of samples with low ( left ) and high ( right ) expression, respectively. Black arrows mark examples of expression of NR4A2 and MUC5B in tumor cells, while blue arrows mark expression in non-malignant cells.

Journal: Cancers

Article Title: Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects

doi: 10.3390/cancers15041298

Figure Lengend Snippet: Representative immunohistochemistry staining of DLBCL lymphoma tissue for NR4A2 ( A ) and MUC5B ( B ). Immunohistochemical staining of DLBCL for NR4A2 ( A ) and MUC5B ( B ). Representative staining of samples with low ( left ) and high ( right ) expression, respectively. Black arrows mark examples of expression of NR4A2 and MUC5B in tumor cells, while blue arrows mark expression in non-malignant cells.

Article Snippet: The human ABC DLBCL cell line U2932 used in this study was obtained from DSMZ (Leibniz Institute, Braunschweig, Germany) and cultured as previously described [ ].

Techniques: Immunohistochemistry, Staining, Immunohistochemical staining, Expressing

Correlation between NR4A2 expression and overall survival among female ABC DLBCL patients. NR4A2 expression data for each individual female ABC DLBCL and individual survival data were obtained from the EGAD00001003600 data set. Optimal cut point for high vs. low NR4A2 expression was determined using maximally selected rank statistics from the “maxstat” R package. The number of individuals with high and low NR4A2 expression after optimal cut point determination was 55 and 77, respectively. The R packages “survival” and “survminer” were used for the survival analysis. The pink and blue areas show lower 95% to upper 95% CI for low and high NR4A2 expression, respectively. p = 0.008 for the difference in survival between the high and low NR4A2 -expressing individuals.

Journal: Cancers

Article Title: Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects

doi: 10.3390/cancers15041298

Figure Lengend Snippet: Correlation between NR4A2 expression and overall survival among female ABC DLBCL patients. NR4A2 expression data for each individual female ABC DLBCL and individual survival data were obtained from the EGAD00001003600 data set. Optimal cut point for high vs. low NR4A2 expression was determined using maximally selected rank statistics from the “maxstat” R package. The number of individuals with high and low NR4A2 expression after optimal cut point determination was 55 and 77, respectively. The R packages “survival” and “survminer” were used for the survival analysis. The pink and blue areas show lower 95% to upper 95% CI for low and high NR4A2 expression, respectively. p = 0.008 for the difference in survival between the high and low NR4A2 -expressing individuals.

Article Snippet: The human ABC DLBCL cell line U2932 used in this study was obtained from DSMZ (Leibniz Institute, Braunschweig, Germany) and cultured as previously described [ ].

Techniques: Expressing

Inhibition of estrogen synthesis by the aromatase inhibitor letrozole stimulates the growth of U2932 tumors and affects the expression of NR4A and MUC5B . ( A ), Male NSG mice were injected subcutaneously with U2932 cells and treated subcutaneously daily with vehicle or the aromatase inhibitor letrozole (10 μg/mouse). The vehicle group consisted of 7 mice, letrozole group consisted of 8 mice. Tumor size was measured daily. ( B ), RT-qPCR analysis of NR4A1 , NR4A2 , NR4A3 and MUC5B . Results are presented as relative expressions (mean ± SD). An unpaired two-tailed t-test was used for statistical analysis between the two groups (* p < 0.05, ** p < 0.01).

Journal: Cancers

Article Title: Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects

doi: 10.3390/cancers15041298

Figure Lengend Snippet: Inhibition of estrogen synthesis by the aromatase inhibitor letrozole stimulates the growth of U2932 tumors and affects the expression of NR4A and MUC5B . ( A ), Male NSG mice were injected subcutaneously with U2932 cells and treated subcutaneously daily with vehicle or the aromatase inhibitor letrozole (10 μg/mouse). The vehicle group consisted of 7 mice, letrozole group consisted of 8 mice. Tumor size was measured daily. ( B ), RT-qPCR analysis of NR4A1 , NR4A2 , NR4A3 and MUC5B . Results are presented as relative expressions (mean ± SD). An unpaired two-tailed t-test was used for statistical analysis between the two groups (* p < 0.05, ** p < 0.01).

Article Snippet: The human ABC DLBCL cell line U2932 used in this study was obtained from DSMZ (Leibniz Institute, Braunschweig, Germany) and cultured as previously described [ ].

Techniques: Inhibition, Expressing, Injection, Quantitative RT-PCR, Two Tailed Test

The gene expression profiling interactive analysis through the GEPIA software. DLBCL data were analyzed in TCGA and GTEx databases through the GEPIA web-based software, showing that G9a was more highly expressed in DLBCL tumor tissues than in normal tissues. Abbreviations: The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx), adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), uveal melanoma (UVM) (*, p < 0.05).

Journal: Cancers

Article Title: High G9a Expression in DLBCL and Its Inhibition by Niclosamide to Induce Autophagy as a Therapeutic Approach

doi: 10.3390/cancers15164150

Figure Lengend Snippet: The gene expression profiling interactive analysis through the GEPIA software. DLBCL data were analyzed in TCGA and GTEx databases through the GEPIA web-based software, showing that G9a was more highly expressed in DLBCL tumor tissues than in normal tissues. Abbreviations: The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx), adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), uveal melanoma (UVM) (*, p < 0.05).

Article Snippet: Human DLBCL cell lines (U2932, HT, SU-DHL-5, and RC-K8) were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and the Bioresource Collection and Research Center (BCRC, Hsinchu, Taiwan).

Techniques: Gene Expression, Software, Expressing

Figure 2. Iron chelators and ironomycin inhibit DLBCL cell growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 2. Iron chelators and ironomycin inhibit DLBCL cell growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Incubation, Concentration Assay, ATP Assay, MANN-WHITNEY, Cytometry

Figure 4. Iron chelators and ironomycin induce ROS production in DLBCL cells. A and B, Effect of deferoxamine, deferasirox, and ironomycin on the ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe for OCI-LY3 (A) and DB cell line (B) at 48 hours. C, Vehicle and GSH treatment (5 and 0.5 mmol/L, respectively, 1 hour) was used as a negative control and oxygen peroxide (10 mmol/L, 1 hour) as a positive control. For the ROS reversion assay, DB cells were treated with 250 nmol/L Ironomycin for 48 hours with or without GSH or Fer-1 or deferoxamine (DFO). ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe. Chaetocin and erastin were used as positive control for GSH and Fer-1 reversion, respectively. Results represent the mean percentage and SD of three independent experiments. , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001; NS, nonsignificant; with paired Student t test.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 4. Iron chelators and ironomycin induce ROS production in DLBCL cells. A and B, Effect of deferoxamine, deferasirox, and ironomycin on the ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe for OCI-LY3 (A) and DB cell line (B) at 48 hours. C, Vehicle and GSH treatment (5 and 0.5 mmol/L, respectively, 1 hour) was used as a negative control and oxygen peroxide (10 mmol/L, 1 hour) as a positive control. For the ROS reversion assay, DB cells were treated with 250 nmol/L Ironomycin for 48 hours with or without GSH or Fer-1 or deferoxamine (DFO). ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe. Chaetocin and erastin were used as positive control for GSH and Fer-1 reversion, respectively. Results represent the mean percentage and SD of three independent experiments. , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001; NS, nonsignificant; with paired Student t test.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Cytometry, Negative Control, Positive Control

Figure 7. Ironomycin presents a significant toxicity on DLBCL primary cells and potentializes doxorubicin cytotoxicity. A, Primary DLBCL cells were treated with ironomycin and/or doxorubicin and incubated during 96 hours with CD40L. DLBCL cell toxicity was analyzed by flow cytometry. B, Hematopoietic progenitor CFU assay were performed with CD34þ cells from apheresis of 5 donors. Cells were cultured in hydroxyl-methyl-cellulose medium with or without conventional chemotherapy or ironomycin. CFU-C, CFU-E, and CFU-GM were counted after 14-day culture. C, The toxicity of ironomycin alone or in combination with doxorubicin on normal CD3þ cells was assessed by flow cytometry. Results represent the median interquartile ranges of each population (n ¼ 5 patients). Statistical significance was tested using t test of pairs: , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001. D, Primary DLBCL cells of 6 patients and PBMC of a healthy donor were incubated with 5 mmol/L Rho-Nox1 Fe2þ probe. The MFI was assessed by flow cytometry in CD20þ DLBCL cells and CD20 cells (microenvironment cells). E, DB cells were treated with increasing concentrations of ironomycin com- bined with doxorubicin for 96 hours, and cell viability was tested by ATP quantification to obtain the viability matrix. The synergy matrix was calculated as described in Materials and Methods.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 7. Ironomycin presents a significant toxicity on DLBCL primary cells and potentializes doxorubicin cytotoxicity. A, Primary DLBCL cells were treated with ironomycin and/or doxorubicin and incubated during 96 hours with CD40L. DLBCL cell toxicity was analyzed by flow cytometry. B, Hematopoietic progenitor CFU assay were performed with CD34þ cells from apheresis of 5 donors. Cells were cultured in hydroxyl-methyl-cellulose medium with or without conventional chemotherapy or ironomycin. CFU-C, CFU-E, and CFU-GM were counted after 14-day culture. C, The toxicity of ironomycin alone or in combination with doxorubicin on normal CD3þ cells was assessed by flow cytometry. Results represent the median interquartile ranges of each population (n ¼ 5 patients). Statistical significance was tested using t test of pairs: , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001. D, Primary DLBCL cells of 6 patients and PBMC of a healthy donor were incubated with 5 mmol/L Rho-Nox1 Fe2þ probe. The MFI was assessed by flow cytometry in CD20þ DLBCL cells and CD20 cells (microenvironment cells). E, DB cells were treated with increasing concentrations of ironomycin com- bined with doxorubicin for 96 hours, and cell viability was tested by ATP quantification to obtain the viability matrix. The synergy matrix was calculated as described in Materials and Methods.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Incubation, Cytometry, Colony-forming Unit Assay, Cell Culture

Figure 8. Ironomycin induces mortality and TFR1 downregulation in primary DLBCL cells. A, Primary DLBCL cells from four patients were cultured with recombinant CD40 L in the presence or absence of ironomycin (500 nmol/L). After 96 hours, cell death of DLBCL cells was monitored by Annexin V/PI staining using flow cytometry. Results represent the mean SD. B, Primary samples of patients with DLBCL were cultured with recombinant CD40 L in presence or absence ironomycin (500 nmol/L). DLBCL cell membrane TFR1 (CD71) expression was assessed by flow cytometry. , P < 0.05; , P < 0.01.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 8. Ironomycin induces mortality and TFR1 downregulation in primary DLBCL cells. A, Primary DLBCL cells from four patients were cultured with recombinant CD40 L in the presence or absence of ironomycin (500 nmol/L). After 96 hours, cell death of DLBCL cells was monitored by Annexin V/PI staining using flow cytometry. Results represent the mean SD. B, Primary samples of patients with DLBCL were cultured with recombinant CD40 L in presence or absence ironomycin (500 nmol/L). DLBCL cell membrane TFR1 (CD71) expression was assessed by flow cytometry. , P < 0.05; , P < 0.01.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Cell Culture, Recombinant, Staining, Cytometry, Membrane, Expressing